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Background: Transient episodes of ischemia in a remote organ or tissue (remote ischemic preconditioning, RIPC)
can attenuate myocardial injury. Myocardial damage is associated with tissue remodeling and the matrix
metalloproteinases 2 and 9 (MMP-2/9) are crucially involved in these events. Here we investigated the effects of
RIPC on the activities of heart tissue MMP-2/9 and their correlation with serum concentrations of cardiac troponin
T (cTnT), a marker for myocardial damage.
Methods: In cardiosurgical patients with cardiopulmonary bypass (CPB) RIPC was induced by four 5 minute cycles
of upper limb ischemia/reperfusion. Cardiac tissue was obtained before as well as after CPB and serum cTnT
concentrations were measured. Tissue derived from control patients (N = 17) with high cTnT concentrations
(≥0.32 ng/ml) and RIPC patients (N = 18) with low cTnT (≤0.32 ng/ml) was subjected to gelatin zymography to
quantify MMP-2/9 activities.
Results: In cardiac biopsies obtained before CPB, activities of MMP-2/9 were attenuated in the RIPC group (MMP-2:
Control, 1.13 ± 0.13 a.u.; RIPC, 0.71 ± 0.12 a.u.; P < 0.05. MMP-9: Control, 1.50 ± 0.16 a.u.; RIPC, 0.87 ± 0.14 a.u.; P < 0.01),
while activities of the pro-MMPs were not altered (P > 0.05). In cardiac biopsies taken after CPB activities of pro- and
active MMP-2/9 were not different between the groups (P > 0.05). Spearman’s rank tests showed that MMP-2/9
activities in cardiac tissue obtained before CPB were positively correlated with postoperative cTnT serum levels
(MMP-2, P = 0.016; MMP-9, P = 0.015).
Conclusions: Activities of MMP-2/9 in cardiac tissue obtained before CPB are attenuated by RIPC and are
positively correlated with serum concentrations of cTnT. MMPs may represent potential targets for RIPC mediated
cardioprotection.
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Cardiac surgery with cardiopulmonary bypass is gener-
ally associated with a predictable incidence of myocar-
dial, neurological, and renal ischemia/reperfusion injury
leading to an increased risk of post-operative myocardial
stunning, neurological deficits, acute renal failure and as
a result increased mortality [1-3].
Ischemic preconditioning in which transient episodes of
ischemia are applied before prolonged ischemia/reperfu-
sion injury has been shown to reduce myocardial damage
resulting in cardioprotection [4-8]. Ischemic precondition-
ing does not only act locally, but also protects remote
tissues from ischemia/reperfusion injury, a phenomenon
known as remote ischemic preconditioning (RIPC). Stud-
ies in patients reported that transient limb ischemia atten-
uates myocardial injury in a number of clinical situations,
including coronary artery surgery, congenital heart sur-
gery, and non-cardiac surgery of high-risk patients
[6,8-15]. In our recent study we investigated cellular and
molecular effects of RIPC in heart tissue of cardiosurgical
patients with cardiopulmonary bypass (CPB) and showed
that RIPC regulates HIF-1α levels, apoptosis and inflam-
mation [16]. The clinical outcome of ischemia/reperfusion
injury in the heart is also strongly dependent on remodel-
ing processes within the myocardial tissue. Matrix metal-
loproteinases (MMPs), are members of the metzincin
group of proteases, which are named after the zinc ion
and the conserved Met residue at the active site [17] and
especially MMP-2 and MMP-9 are believed to play a key
role in remodeling processes within the myocardial tissue
[18,19]. Besides their involvement in tissue remodeling,
various other biological consequences are also based on
the proteolytic activities or MMPs: MMPs regulate several
chemokines and affect cell survival as well as cell prolifer-
ation. Moreover, MMPs induce cell differentiation and are
also able to activate latent signaling molecules or inacti-
vate soluble mediators [20]. Based on their multiple func-
tions, MMPs may therefore represent so far neglected
cellular targets for RIPC-mediated cardioprotection.
In the study presented, we investigated the effect of
RIPC on the activities of MMP-2 and MMP-9 in cardiac
biopsies obtained from cardiosurgical patients before
and after CPB and screened for a possible correlation of




The study protocol, patient information, and informed
consent were approved by the Ethics Committee of the
University Hospital Schleswig-Holstein, Campus Kiel,
Germany (Reference number: A165/08). The study was
performed in accordance with the fourth revision of
the Declaration of Helsinki (1996) and is registered atClinicalTrials.gov (NCT00877305). Employing patient
sera and biopsy material an experimental substudy has
been published recently [16] and clinical data focusing
on neurocognitive outcome have been presented by
Meybohm et al [21]. Aim of the actual study was to in-
vestigate a possible involvement of MMP-2/9 activity in
RIPC-mediated cardioprotection and patients included
into the study were selected based on blood levels of
cardiac troponin T (cTnT; for details see below). Each
patient (age ≥ 18 years) gave written informed consent
to participate in the study. All types of cardiac surgery
in which cardiopulmonary bypass (CPB) was used were
included. Patients were randomized to group RIPC or
control in a double-blinded fashion. RIPC was induced
by four cycles of upper limb ischemia (5-minutes blood-
pressure cuff inflation to 200 mmHg and 5-minutes cuff
deflation) after induction of total intravenous anaesthesia
(propofol and sufentanil). RIPC treatment was predomin-
antly assigned to the left upper arm. In patients assigned
to the control group we used four cycles of 5-minutes
blood-pressure cuff inflation to 20 mmHg and 5-minutes
cuff deflation without any limb ischemia (Figure 1A).
Basic and clinical information about the respective pa-
tients included in the experiments are displayed in Tables 1
and 2.
Tissue and serum samples
Cardiac tissue of the right atrium was collected from
RIPC and control patients before as well as after CPB.
cTnT values were obtained for each patient at the fol-
lowing time points: (i) before surgery, (ii) at intensive
care unit (ICU) admission, (iii) after 12 h, (iv) after 24 h,
and (v) after 48 h. As in our previous study statistically
significant differences in cTnT concentrations between
control and RIPC patients were only detected at ICU ad-
mission [16], all further analyses were performed with
cTnT data from this time point. Quantifications of cTnT
were performed by the Department of Clinical Chemistry
of the University Hospital Schleswig-Holstein, Campus
Kiel, Germany. All tissue und serum samples analyzed in
the study were derived from the collective of the patients
employed in our recently published work [16]. The mean
concentration of cTnT in the patients investigated was
0.42 ± 0.05 ng/ml (median: 0.32 ng/ml [0.19/0.57]; [1st/3rd]
percentile). In order to optimize the experimental setup
for the analyses of a possible involvement of MMP-2/9 in
RIPC-mediated cardioprotection (classified by cTnT levels),
we established subgroups of patients based on blood con-
centrations of cTnT. Only cardiac tissue from control pa-
tients with high cTnT concentrations (≥0.32 ng/ml at ICU
admission) indicative of myocardial damage [22] and from
RIPC patients with low cTnT concentrations, indicative of
cardioprotection (“responder”; ≤0.32 ng/ml at ICU admis-






































Figure 1 Experimental setting and serum cardiac troponin T (cTnT) concentrations in control and RIPC patients. RIPC was performed by
4 cycles of 5 minutes of upper arm ischemia induced with a blood pressure cuff. Each cycle of ischemia was followed by 5 minutes of reperfusion.
Cardiac biopsies were obtained before and after CPB (A). cTnT levels were evaluated at ICU admission in the control and RIPC group (B). Bars denote
SEM; ***, P < 0.001. cTnT, cardiac troponin T; CPB, cardiopulmonary bypass; ICU, intensive care unit; RIPC, remote ischemic preconditioning.
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Protein extraction from tissue biopsies was performed
with RIPA buffer containing 150 mM sodium chloride,
1.0% NP-40, 0.1% sodium dodecyl sulfate (SDS), 1% so-
dium deoxycholate, 50 mM Tris-HCl (pH 7.6; all from
Sigma-Aldrich, Hamburg, Germany). Protein concentra-
tions were determined with a BCA Protein Assay kit
(RotiQ, Carl Roth, Karlsruhe, Germany). Zymography
was performed as described previously [23,24]. Briefly,
30 μg of the respective tissue was loaded and separated
on 7% SDS polyacrylamide gels (containing 1 mg/ml
gelatin) under non-reducing conditions. After electro-
phoresis the gels were soaked in 2.5% Triton X-100 for
30 minutes to remove SDS and incubated in Tris-HCl
(50 mmol/l, pH 7.5), containing CaCl2 (5 mmol/l), and
ZnCl2 (1 mmol/l) overnight at 37 °C. After Coomassie
blue staining white bands indicated digestion of gelatin
by MMPs. Densitometric analysis was performed usingthe ImageJ 1.41o software (ImageJ, NIH, USA). As even
slight differences in the treatment procedure of the gel-
atin gels (e.g. incubation time, staining and destaining
protocols) resulted in variations in the signal intensities
between the respective gels, a control of human recom-
binant MMP-2 (0.1 ng; #PF023, Merck, Darmstadt,
Germany) was loaded on each gel and signal intensities
of the MMP bands were related to the signal intensity of
0.1 ng MMP-2 on the respective gel.Statistical analysis
Statistics were performed using the software GraphPad
Prism version 5.01 for Windows. Categorical variables
were compared using the Fisher’s exact test. Each data set
was tested for normality using the D’Agostino and Pearson
omnibus test and student’s t-tests were performed. For
MMP-2/9 and cTnT correlations, the Spearman’s rank
Table 1 Basic and clinical data of RIPC and control
patients
Variable Control (N = 17) RIPC (N = 18) P-value
Demographic data
Male (N) 17 (100%) 14 (77.8%) 0.10
Female (N) 0 (0%) 4 (22.2%) 0.10
Age (years) 63 ± 9 68 ± 11 0.03
Weight (kg) 86 ± 9.5 80 ± 11 0.04
BMI (kg/m2) 28 ± 3.2 26 ± 3.6 0.04
Type of surgery
CABG (N) 9 (52.9%) 13 (72.2%) 0.31
AVR (N) 2 (11.8%) 2 (11.1%) 1.00
Combi (N) 6 (35.3%) 3 (16.7%) 0.26
Perioperative data
Bypass time (min) 128 ± 34 108 ± 51 0.01
Aortic clamping time (min) 86 ± 25 70 ± 36 0.01
EuroSCORE 3 ± 2 4 ± 2 0.03
AVR, aortic valve replacement; BMI, body mass index; CABG, coronary artery
bypass graft; Combi, combined surgery.








Diabetes mellitus (N) 3 (17.6%) 4 (22.2%) 1.00
Hypercholesterolemia (N) 12 (70.6%) 9 (50.0%) 0.31
Stroke (N) 2 (11.8%) 1 (5.5%) 0.60
Arterial hypertension (N) 14 (82.3%) 15 (83.3) 1.00
Myocardial infarction (N) 3 (17.6%) 7 (38.8%) 0.26
Medications
Beta-adrenergic-blockers (N) 10 (58.8%) 13 (72.2%) 0.49
ACE/AT-1-antagonists (N) 11 (64.7%) 8 (44.4%) 0.31
ASA/clopidogrel (N) 14 (82.3%) 13 (72.2%) 0.69
Calcium-channel blockers (N) 1 (5.9%) 3 (16.6%) 0.60
Cholesterol-lowering (N) 8 (47.1%) 9 (50.0%) 1.00
Insulin/metformin (N) 2 (11.8%) 3 (16.6%) 1.00
Diuretics (N) 5 (29.4%) 3 (16.6%) 0.44
ICU data
ICU-stay (hours) 59 ± 57 28 ± 23 0.13
ICU-readmission (N) 0 (0%) 1 (5.5%) 1.00
Reoperation (N) 1 (5.9%) 0 (0%) 0.49
Arrythmia (N) 4 (23.5%) 7 (38.8%) 0.47
Ventilation time (hours) 26 ± 25 14 ± 5 0.15
Reintubation (N) 3 (17.6%) 1 (5.5%) 0.34
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expressed as mean ± SEM.
Results
Serum concentrations of cTnT and clinical parameters of
RIPC patients
cTnT concentrations are elevated in the blood after
myocardial tissue damage [22,27,28]. In a study includ-
ing 61 patients we showed that RIPC significantly re-
duced cTnT levels in the blood of cardiosurgical
patients directly after admission to the intensive care
unit (ICU; control, 0.60 ± 0.06 ng/ml; RIPC, 0.45 ±
0.06 ng/ml; P < 0.05; [16]). However, cTnT levels were
only by trend reduced by RIPC in our recent study
which included a total of 90 control and 90 RIPC pa-
tients [21]. Here, 17 control patients with mean cTnT
concentrations of 0.63 ± 0.06 ng/ml and 18 RIPC patients
with mean cTnT concentrations of 0.20 ± 0.02 ng/ml
(P < 0.001, Figure 1B) were included into the study and
subjected to further analyses. In addition to the signifi-
cant reduction of cTnT concentrations in the RIPC
group, RIPC patients also exhibited a by trend shorter
mean residence time at the ICU (control, 59 ± 57 h;
RIPC, 28 ± 23 h; Table 2) which was accompanied by a
reduced ventilation time (control, 26 ± 25 h; RIPC, 14 ±
5 h; Table 2).
MMP-2 and MMP-9 activities in cardiac tissue obtained
before CPB are attenuated in RIPC patients
Biological consequences of increased or decreased MMP
activities are complex and include tissue remodeling, cell
proliferation, cell death, inactivation of soluble mediators
and activation of latent signaling molecules [20]. We
show that in cardiac biopsies taken before CPB, activities
of pro-MMP-2 and pro-MMP-9 were not altered (P >
0.05; Figure 2 A, E, I) while the activities of MMP-2 and
MMP-9 were significantly lower in RIPC patients com-
pared to the control group (MMP-2: RIPC, 0.71 ± 0.12 a.u.;
Control, 1.13 ± 0.13 a.u.; P < 0.05. MMP-9: RIPC, 0.87 ±
0.14 a.u.; Control, 1.50 ± 0.16 a.u.; P < 0.01; Figure 2 C,
G, I). In cardiac biopsy samples that were obtained after
CPB, activities of pro- and active MMP-2 and MMP-9
were not different between the control and RIPC group
(P > 0.05; Figure 2 B, D, F, H, J). Additional control ex-
periments were performed using cardiac tissue samples
from RIPC patients with high cTnT levels (“non-re-
sponder”; cTnT ≥0.32 ng/ml; mean cTnT concentration
1.04 ± 0.14 ng/ml; N = 12) and control patients with low
cTnT blood concentrations (cTnT ≤0.32 ng/ml; mean
cTnT concentration 0.18 ± 0.02 ng/ml; N = 12). The re-
sults show an opposite trend in the correlation between
RIPC and MMP-2/9 activity. Compared to the control
group, the activities of MMP-2 and MMP-9 in cardiac































































































































































































Figure 2 (See legend on next page.)
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Figure 2 MMP activities in cardiac biopsy samples. The enzymatic activities of pro-MMP-2, MMP-2, pro-MMP-9 and MMP-9 were evaluated in
tissue samples taken before CPB (A, C, E, G) and after CPB (B, D, F, H) using gelatin zymography. One representative gel containing 6 control
and 6 RIPC samples is shown in I (before CPB) and J (after CPB). Bars denote SEM; *, P < 0.05; **, P < 0.01. CPB, cardiopulmonary bypass;
RIPC, remote ischemic preconditioning.
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gate whether the effects of RIPC on MMP-2/9 activities
are mediated via the regulation of protein expression
levels, Westernblotting experiments were performed and
revealed that RIPC did not change the relative amounts of
MMP-2 and MMP-9 protein in cardiac tissue derived be-
fore or after CPB (Additional file 2: Figure S2).
Serum concentrations of cTnT are positively correlated
with MMP-2 and MMP-9 activities in cardiac tissue
obtained before CPB
As RIPC was related to decreased activities of MMP-2
and MMP-9 in cardiac biopsies obtained before CPB
(Figure 2 C, G, I), we next investigated whether the ac-
tivities of cardiac tissue MMP-2 and MMP-9 also corre-
lated with postoperative serum concentrations of cTnT,
a well-recognized marker of myocardial tissue damage
[22,27,28]. Spearman’s rank tests [25,26] showed that
MMP-2 and MMP-9 activities in cardiac tissue biopsies
obtained before CPB were positively correlated with cTnT
serum levels (MMP-2/cTnT: Spearman r, 0.40; P = 0.016.
MMP-9/cTnT: Spearman r, 0.41; P = 0.015; Figure 3 A, B).
No significant correlation between cTnT concentrations
and MMP-2/9 activity was found in samples taken after
CPB (MMP-2/cTnT: Spearman r, 0.12; P = 0.496. MMP-9/
cTnT: Spearman r, -0.02; P = 0.919; Figure 3 C, D).
Discussion
Remote ischemic preconditioning (RIPC) is a straightfor-
ward and efficient method to protect the heart from ische-
mia/reperfusion injury which appears during various
surgical procedures [8,10,12,15,16,29,30]. Although, recent
studies clearly showed the capacity of RIPC in the clinic,
cellular and molecular mechanisms of RIPC within the
heart are only poorly investigated [31,32]. Detailed infor-
mation about the RIPC-mediated events and target mole-
cules could however increase the effectiveness of RIPC
leading to improved patient outcome.
Cardiac surgery with cardiopulmonary bypass (CPB) is
frequently associated with ischemia/reperfusion injury
leading to cell death and subsequent tissue remodeling
[33,34]. MMP-2 and MMP-9 are believed to play a key
role in the ischemia/reperfusion induced myocardial re-
modeling processes and may therefore represent poten-
tial targets for cardioprotective interventions such as
RIPC [8,18,33,35]. Employing a pig model of cardiac ar-
rest following left anterior descending coronary artery is-
chemia, we showed a significantly increased enzymaticactivity of MMP-9 in the ischemic myocardial tissue
[36]. Moreover, we recently demonstrated that RIPC re-
duces the activities of MMP-2 and MMP-9 in sera of
cardiosurgical patients [24]. Here we reveal that tissue
activities of MMP-2 and MMP-9 are also attenuated by
RIPC in cardiac biopsies obtained before CPB. Our find-
ings suggest a possible connection between MMP activ-
ities and ischemia/reperfusion induced cardiac damage,
supporting the idea that low MMP-2/9 activities may be
associated with reduced ischemia/reperfusion injury.
How the ischemic preconditioning in a remote organ
(upper limb) can lead to a reduction of MMP-2/9 activ-
ity in cardiac tissue is still unclear. In general, three main
mechanisms may be responsible for transmitting the
protective signal from the organ or tissue, in which the
RIPC stimulus is applied, to the target organ or tissue:
(i) Neural pathways. (ii) The release of circulating
humoral factor(s). (iii) Activation of a systemic protect-
ive effect (e.g. anti-inflammatory response) [29]. It is not
yet known if and how these pathways are interconnected
and how they could influence the activities of tissue
MMPs. However, MMP function can be regulated at
many levels. In addition to RNA transcription and pro-
tein synthesis, MMP function can be controlled at the
levels of secretion, intracellular trafficking, subcellular or
extracellular localization, activation of the zymogen
form, expression of MMP specific endogenous protein
inhibitors, such as tissue inhibitors of metalloproteinases
(TIMPs) and alpha2-macroglobulin, and protease deg-
radation [20]. As in our study RIPC regulated enzymatic
activities, but not protein levels of MMP-2/9, inhibitory
molecules like TIMPs and alpha2-macroglobulin may be
suggested as potential targets of the RIPC mediated at-
tenuation of MMP activity. Interestingly, MMP-2/9 ac-
tivities were not regulated by RIPC in tissue samples
taken after CPB. This finding might be based on the fact
that the immunological response to the extracorporeal
circulation during CPB generates a systemic inflammatory
response syndrome (SIRS), that is associated with the re-
lease of various pro-and anti-inflammatory cytokines
[37,38] which may influence the activities of cardiac
MMP-2/9, masking the RIPC-mediated effects in tissue
obtained after CPB. On the other hand, there is also the
possibility that RIPC-mediated effects appear very early
after induction of RIPC and are of only short and transi-
tory nature. It is known that ischemic preconditioning
represents a biphasic phenomenon with a first and a
second window of protection and similar mechanisms
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P=0.015
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Figure 3 Correlation of cardiac tissue MMP-2/9 activities and serum cardiac troponin T (cTnT) levels. cTnT concentrations were measured
at admission to the intensive care unit (ICU) and were correlated with the activities of MMP-2 and MMP-9 in heart tissue samples obtained before
CPB (A, B) and after CPB (C, D). CPB, cardiopulmonary bypass; cTnT, cardiac troponin T.
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The early phase of protection develops quickly within mi-
nutes from the initial ischemic conditioning event and
lasts for 2 to 3 hours. This is followed by a delayed phase
that begins after 12 to 24 hours and lasts up to 4 days. In
our study, intraoperative ischemia falls into the first win-
dow of protection. The mechanisms of the two phases of
protection are believed to be of very different nature.
While the early phase is caused by rapid modification
and/or activation of pre-existing proteins, the delayed
phase requires synthesis of new proteins. [39,40]. This
may explain our observation that activities of MMP-2 and
MMP-9 are regulated by RIPC, while we did not observe
effects of RIPC on the protein levels of both MMPs. The
fact that the first window of protection only lasts for 2-3
hours could also be responsible for our findings that
changes in MMP activities were only evident shortly after
RIPC, at the beginning of the surgical procedure but not
anymore at the end of surgery.
Blood concentrations of cTnT are typically increased
after myocardial injury [22,27,28]. In our previous study
we showed that serum concentrations of cTnT are re-
duced in patients receiving RIPC [16] an observation
that has also been made by others, pointing towardscardioprotective effects of RIPC [8,10,12,15,41]. In the
study presented, we found a positive correlation of tissue
MMP-2/9 activities in cardiac biopsies taken before CPB
and serum levels of cTnT at ICU admission. These data
once more support the idea that the RIPC-associated re-
duction of cardiac tissue MMP-2 and MMP-9 activities
may be directly or indirectly involved in RIPC-mediated
cardioprotection. Serum cTnT levels did not correlate
with MMP-2/9 activities in cardiac tissue taken after
CPB. This observation may be related to the SIRS gener-
ated by the extracorporeal circulation during CPB, a
short and only transitory effect of RIPC on MMP-2/9 ac-
tivities or other yet unidentified mechanisms induced by
the surgical or anaesthetic procedure.
There are several limitations of the study, which have
to be considered: (i) Due to surgical restrictions and re-
fusal of several patients to the procedure of biopsy re-
trieval, cardiac tissue could not be obtained from all
patients that participated in the initial study (Clinical-
Trials.gov; NCT00877305). (ii) In the case that biopsies
were taken from the respective patients, only a limited
amount of tissue (<1 mm2) was available for biochemical
analyses. (iii) Based on surgical limitations only cardiac
tissue of the right atrium and no ventricular tissue could
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directly after RIPC (before CPB). As the second biopsy
was collected immediately after CPB, the time period be-
tween the collection of the first and second sample var-
ied between the patients and was determined by the
length of the surgical procedure. (v) Although, there were
no differences in co-morbidities, medications and ICU
data between control and RIPC patients, some of the peri-
operative parameters differed between the groups. While
bypass time and aortic clamping time were lower in RIPC
patients possibly resulting in reduced perioperative stress
and tissue damage, age, weight and EuroSCORE were all
significantly higher in the RIPC group predisposing these
patients to an increased peri- and postoperative myocar-
dial damage. Moreover, while the control group consisted
only of male patients (17/17), 22% of the patients in the
RIPC group were female (4/18). The differences in gender
distribution did not reach statistically significant levels,
however we cannot exclude that the gender variations be-
tween the groups may have at least to some extend influ-
enced the results of the study, especially as several clinical
observations suggest increased resistance of the female
heart to ischemia/reperfusion injury [15,42].
Conclusions
Our study performed with tissue and serum samples
from cardiosurgical patients showed that activities of
MMP-2/9 in cardiac tissue obtained before CPB are at-
tenuated by RIPC and are positively correlated with
serum concentrations of cTnT, suggesting that MMP-2/
9 may be involved in RIPC-mediated cardioprotection.
However, additional studies have to clarify whether the
observed reduction of cardiac MMP-2/9 activities by
RIPC is causally related to RIPC-mediated cardioprotec-
tion and if a modulation of MMP-2/9 activities has the
potential to augment the cardioprotective efficacy of
RIPC in cardiosurgical patients.Additional files
Additional file 1: Figure S1. MMP activities in cardiac biopsy samples.
The enzymatic activities of pro-MMP-2, MMP-2, pro-MMP-9 and MMP-9
were evaluated in tissue samples from 12 control patients with low cTnT
levels (cTnT ≤0.32 ng/ml; mean cTnT concentration 0.18 ± 0.02 ng/ml)
and 12 RIPC patients with high cTnT concentrations (“non-responder”;
cTnT ≥0.32 ng/ml; mean cTnT concentration 1.04 ± 0.14 ng/ml).
Compared to the control group the activities of both MMPs were by trend
increased in the RIPC group with high cTnT levels. Bars denote SEM. CPB,
cardiopulmonary bypass; RIPC, remote ischemic preconditioning.
Additional file 2: Figure S2. Proteinexpression of MMP-2/9.
Westernblotting experiments were performed using cardiac tissue
derived before CPB (A, C) and after CPB (B, D). Antibodies against MMP-2
(A, B) and MMP-9 (C, D) were employed and the intensity of the respective
signal was related to the intensity of actin. One representative Westernblot
containing samples from 6 control and 6 RIPC patients is shown in
E (before CPB) and F (after CPB). Bars denote SEM.Competing interests
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